Australian Specialized REITs Stock News

Mirvac Group (ASX:MGR) has put fresh numbers on the table for H1 2026, with revenue of A$1.5b and basic EPS of A$0.017, setting the tone for how its earnings profile is evolving at a A$2.04 share price. The group has seen revenue move from A$1.8b in H2 2024 to A$1.2b in H1 2025 and then to A$1.5b in H2 2025, while basic EPS shifted from a loss of A$0.153 in H2 2024 to A$0.0003 in H1 2025 and A$0.017 in H2 2025. This progression gives investors a clearer read on how margins are tracking across...

Lottery (ASX:TLC) has laid out its H1 2026 scorecard, reporting revenue of A$1.97b and basic EPS of A$0.085. The company has seen revenue move from A$2.11b in H2 2024 to A$1.78b in H1 2025 and A$1.97b in H2 2025, while basic EPS has tracked from A$0.088 to A$0.079 and then A$0.085 over the same periods. This gives investors a clearer view of how the top and bottom line are pairing up. With net income at A$189.8m this half and net profit margins holding steady year over year, the latest...

Healius (ASX:HLS) has reported its H1 2026 numbers with revenue of A$688.1 million and a basic EPS loss of A$0.04 per share, keeping the focus firmly on how quickly its earnings profile can stabilise from here. The company has seen first half revenue move from A$620.8 million in H1 2024 to A$688.1 million in H1 2025, while basic EPS has shifted from a loss of A$1.08 per share to a smaller loss of A$0.04 per share. The current release therefore lands against a backdrop of heavy but narrowing...

Vicinity Centres H1 2026 earnings snapshot Vicinity Centres (ASX:VCX) has put fresh numbers on the table for H1 2026, with H2 2025 revenue at A$677.2 million and basic EPS of A$0.112, backed by funds from operations of A$329.7 million. The group has seen recent revenue move from A$669.8 million in H2 2024 to A$702.3 million in H1 2025 and then A$677.2 million in H2 2025, while basic EPS shifted from A$0.071 in H2 2024 to A$0.108 in H1 2025 and A$0.112 in H2 2025. For investors, the mix of...

Challenger Limited (ASX:CGF) recently reported half-year net income of A$338.7 million, sharply higher than a year earlier, lifted interim dividends to 15.5 cents per share, and announced a Board-approved share buyback program subject to APRA approval, with 691,661,481 shares on issue as at 17 February 2026. Taken together, the stronger earnings, higher fully franked dividend and proposed buyback highlight management’s confidence in capital strength and the cash-generating profile of...

Beach Energy Limited has already reported half-year 2025 results showing sales of A$1,040 million, net income of A$150.2 million and lower earnings per share than a year earlier, while declaring a fully franked interim dividend of A$0.01 per share for the six months to 31 December 2025. Alongside a modest production outlook for fiscal 2026, the combination of softer profitability and a reduced dividend sharpens investor focus on how Beach balances capital discipline with shareholder...

Cochlear Limited recently reported half-year 2025 results showing largely flat sales of A$1,167.2 million but lower net income of A$161.5 million and reduced earnings per share versus the prior year. At the same time, the company held its interim franked dividend steady at A$2.15 per share, implying management’s desire to signal confidence despite Nexa rollout and contracting challenges pressuring profit and guidance. We’ll now examine how weaker profit guidance, tied to delays in Nucleus...

Australian Clinical Labs (ASX:ACL) is in focus after reporting half year 2025 results that show lower net income while sales remained close to prior levels, and the company also declared a fully franked interim dividend. See our latest analysis for Australian Clinical Labs. The latest half year result and interim dividend have arrived against a weaker backdrop for shareholders, with the share price at A$2.15 after a 30 day share price return decline of 15.35% and a 1 year total shareholder...

SEEK H1 2026 Earnings: Headline Results SEEK (ASX:SEK) has posted its H1 2026 numbers, with investors looking back to the recent H2 2025 performance, where revenue was A$560.8 million and basic EPS came in at A$0.28, alongside net income from ongoing operations of A$98.5 million. The company reported revenue of A$526.1 million in H2 2024 and A$560.8 million in H2 2025, while EPS shifted from a loss of A$0.25 to a profit of A$0.28 over the same halves. This sets the scene for a results season...

Judo Capital Holdings (ASX:JDO) has put up a solid H1 2026 scorecard, with revenue of A$205.6 million and net income of A$59.9 million, translating to basic EPS of A$0.053504 and setting the tone for how the rest of the year might look. The bank has seen revenue move from A$172.1 million in H1 2025 to A$175.3 million in H2 2025 and then to A$205.6 million in H1 2026, while basic EPS has stepped from A$0.036738 to A$0.040714 to A$0.053504 over the same periods, giving investors a clear view of...

Botanix Pharmaceuticals (ASX:BOT) has drawn fresh attention after filing multiple follow on equity offerings totaling A$45 million. The company is issuing new ordinary shares at A$0.06 with attached options that could reshape its capital structure. See our latest analysis for Botanix Pharmaceuticals. That equity raising lands after a sharp reset in sentiment, with a 1 day share price return showing a 41.33% decline at the latest A$0.066 close and a 1 year total shareholder return of 86.80%...

Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.

Brightstar Resources has entered a fixed-price engineering, procurement and construction partnership with GR Engineering Services to advance its Goldfields Project in Western Australia, targeting construction from April 2026 and first gold production by June 2027 as part of its plan to build a multi-asset gold portfolio. This fixed-price EPC structure is important because it offers cost and schedule certainty, potentially reducing project execution risk for Brightstar’s expansion...

Zip Co (ASX:ZIP) has launched a new brand platform called "In You We Trust". The company has rolled out a national "You Trust Me?" campaign to support the new positioning. Alongside the branding shift, Zip Co is introducing product updates and new app features focused on trust and flexibility. Zip Co operates in digital financial services, where competition from both traditional banks and newer fintechs has been intense. By centering its new platform on trust and customer control, ASX:ZIP...

We'd be surprised if QEM Limited ( ASX:QEM ) shareholders haven't noticed that an insider, Gavin Loyden, recently sold...

Insiders who purchased Micro-X Limited ( ASX:MX1 ) shares in the past 12 months are unlikely to be deeply impacted by...

In the last week, the Australian market has remained flat, but over the past 12 months, it has seen a modest rise of 3.6%, with earnings forecasted to grow by 12% annually. In this environment, selecting dividend stocks with solid yields can be an effective strategy for investors seeking steady income and potential growth in their portfolios.

As Australian shares navigate a modest start to the week amid the bustling February reporting season, investors are keenly observing developments with limited guidance from U.S. and Chinese markets due to their respective holidays. In this environment, growth companies with high insider ownership can offer unique insights into market confidence, as insiders often have a deep understanding of their company's potential and prospects.

As Australian shares prepare for a modest open amid the bustling February reporting season, investors are navigating a market temporarily devoid of guidance from the U.S. and Chinese traders due to respective holidays. In this environment, identifying stocks trading below their estimated intrinsic worth can present valuable opportunities, particularly as companies release their latest financial results and strategic updates.

As Australian shares gear up for a modest open amid the bustling February reporting season, investors are keeping a close watch on the Reserve Bank of Australia's latest policy meeting minutes. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that can offer unique investment opportunities. By focusing on those with solid financial foundations and growth potential, investors might uncover hidden gems in the market.

JB Hi-Fi (ASX:JBH) has kicked off H1 2026 with A$6.1b in revenue and basic EPS of A$2.80, setting the tone for its latest earnings update. The company has seen revenue move from A$5.7b and EPS of A$2.61 in H1 2025 to A$4.9b and A$1.62 in H2 2025, before reaching A$6.1b and A$2.80 in H1 2026. This gives investors a clear view of how sales and EPS have tracked across recent halves. With a trailing net profit margin of 4.4% and steady earnings over the last twelve months, the story now turns to...

BlueScope Steel (ASX:BSL) has kicked off FY26 with H1 revenue of A$8.3b and basic EPS of A$0.88, as investors weigh these headline numbers against a year where margins have come under pressure. The company has seen revenue move from A$7.9b in H1 2025 to A$8.3b in H1 2026, while basic EPS has shifted from A$0.40 to A$0.88 over the same period. This has occurred against a backdrop of modest 3.4% revenue growth, compressed net profit margins at 1.7%, and a large one off loss that dragged on...

Whitefield Income (ASX:WHI) has released its H1 2026 scorecard, with investors watching how the latest A$16.97 million in trailing twelve month revenue and A$13.39 million in net income feed through to EPS of A$0.159634 on a A$1.425 share price. The company has reported revenue of A$2.04 million and EPS of A$0.058984 in H1 2025, followed by A$8.22 million in revenue and EPS of A$0.04039 in H2 2025, contributing to a reported earnings jump of roughly 8x over the past year and a net profit...

Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing that an abstract on its dual targeting Co-PSMA agent has been accepted for oral presentation at the EAU Congress 2026, highlighting progress across multiple prostate cancer imaging trials. See our latest analysis for Clarity Pharmaceuticals. The EAU abstract sits alongside a strong run of short term momentum, with a 7 day share price return of 9.48% and a 30 day share price return of 7.83%. However, the year to date share...